Adaptive Biotechnologies
Presence
Adaptive Biotechnologies is one of the...
Adaptive Biotechnologies is a company listed under the stock ticker ADPT (US).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Adaptive Biotechnologies
- Chad Robins, President, Chief Executive Officer and Director
- Robert Hershberg, Director
- Mike Pellini, Director
Popular executive movements at Adaptive Biotechnologies
- Kyle Piskel, who was Principal Accounting Officer, is promoted to Chief Financial Officer (posted on April 4 2024).
- Tycho Peterson, Chief Financial Officer, has left the company (posted on April 4 2024).
- Kevin Conroy, Director, has left the company (posted on September 12 2023).
Click here to view some more movements at Adaptive Biotechnologies
Create your alert
to follow the executive moves at Adaptive Biotechnologies.
Biotechnology
Adaptive Biotechnologies has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by Adaptive Biotechnologies
- Events - Adaptive Biotechnologies
- Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020 - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference - Adaptive Biotechnologies
- Press Releases - Adaptive Biotechnologies
- Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit - Adaptive Biotechnologies
- Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2 - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease - Adaptive Biotechnologies
- Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock - Adaptive Biotechnologies
- View more press releases Close
Social media about Adaptive Biotechnologies
- Adaptive Biotechnologies on Wikipedia, Google News & Yahoo Finance
- Adaptive Biotechnologies on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Chad Robins 
Call Adaptive Biotechnologies at +1 855...
